Literature DB >> 3107384

Prevention of venous thromboembolism after general surgery. Cost-effectiveness analysis of alternative approaches to prophylaxis.

G Oster, R L Tuden, G A Colditz.   

Abstract

A number of methods of prophylaxis can reduce the risk of postoperative venous thromboembolism in patients undergoing general surgery. The cost-effectiveness of several of these--low-dose subcutaneous heparin, intermittent pneumatic compression, graduated compression stockings, heparin plus dihydroergotamine, heparin plus stockings, and intermittent pneumatic compression plus stockings--was assessed by pooling data from published reports of randomized controlled trials. Using clinical protocols, costs for prophylaxis, diagnosis, and treatment of venous thromboembolism were determined. The expected outcomes and costs of each strategy were then calculated using techniques of decision analysis. The results indicate that stockings are the only prophylactic method that is actually cost-saving. Costs of care average $34 less per admission for patients using stockings than for those receiving no prophylaxis. Most other methods of prophylaxis further reduce thromboembolic risk, but increase costs by $50 to $88 per patient relative to costs for the use of stockings. Differences in the cost-effectiveness of these prophylaxis are more marked, ranging from about $50,000 to almost $500,000 per additional life saved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107384     DOI: 10.1016/0002-9343(87)90149-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.

Authors:  Robin Offord; Adam C Lloyd; Pippa Anderson; Andy Bearne
Journal:  Pharm World Sci       Date:  2004-08

2.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

3.  Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.

Authors:  Jonas Lundkvist; David Bergqvist; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2007-01-16

4.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.

Authors:  L A Levin; D Bergqvist
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Authors:  Peter K Schädlich; Michael Kentsch; Manfred Weber; Wolfgang Kämmerer; Josef Georg Brecht; Vijay Nadipelli; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Venous thromboembolism in Pakistan: a neglected research agenda.

Authors:  Abdul Ahad Khan; Syed Nabeel Zafar
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 8.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Authors:  Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello
Journal:  Blood Adv       Date:  2021-02-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.